MYO16 antisense RNA 1 (non-protein coding) (MYO16-AS1)

MYO16 antisense RNA 1 (MYO16-AS1) is a cytoplasmic long non-coding RNA mainly expressed in lung tissue and identified as a tumor suppressor in lung adenocarcinoma (LUAD). It acts by interacting with the RNA-binding protein IGF2BP3, thereby competitively binding against HK2 mRNA, leading to its destabilization and degradation. This action impairs glucose metabolism and inhibits cancer cell migration, invasion, and proliferation in vitro and in vivo. MYO16-AS1 is tightly regulated by histone modifications at its promoter, with downregulation contributing to poor prognosis and increased tumor aggressiveness. While its most well-studied role is in LUAD, initial evidence suggests relevance in other cancers such as bladder cancer and possible involvement in neurodegenerative disease contexts. These findings propose MYO16-AS1 as a potential biomarker and therapeutic target in cancer biology, though no drugs directly interact with it at present and therapeutic targeting remains investigational.

Other names

MYO16-AS1MYO16 antisense RNA 1 (non-protein coding)NDFIP2/MYO16AS1 fusion

Competitive inhibition (MYO16-AS1 competes with HK2 mRNA for binding to IGF2BP3, influencing mRNA stability and degradation; overexpression leads to decreased tumor cell migration/invasion). Epigenetic regulation (expression levels of MYO16-AS1 are tightly regulated by histone modifications such as H3K27 acetylation).